<DOC>
	<DOCNO>NCT01332565</DOCNO>
	<brief_summary>This study Phase 1 , open label , non-randomized , single dose study determine pharmacokinetics , safety tolerability doultegravir ( DTG ) follow 50 mg single oral administration healthy Japanese subject . A total 10 healthy Japanese subject enrol study receive 50 mg single dose DTG . Subjects screen visit within 30 day prior administration study drug , treatment visit , follow-up visit 7-14 day administration study drug .</brief_summary>
	<brief_title>A Study Investigate Pharmacokinetics , Safety Tolerability GSK1349572 ( Dolutegravir , DTG ) Healthy Japanese Subjects</brief_title>
	<detailed_description>ViiV Healthcare new sponsor study , GlaxoSmithKline process update system reflect change sponsorship</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>The subject healthy Japanese Japanese subject bear Japan 4 ethnic Japanese grandparent must live outside Japan 5 year Japanese passport holder . Healthy judge responsible physician clinically significant abnormality identify medical laboratory evaluation , include 12lead ECG . A subject clinical abnormality laboratory parameter outside reference range age group may include Investigator considers find introduce additional risk factor interfere study procedure . The subject great equal 20 less equal 55 year age , inclusive . A female subject eligible participate : nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 mIU/mL estradiol &lt; 40 pg/mL ( &lt; 147 pmol/L ) confirmatory ] . Childbearing potential agrees use one contraception method list protocol time period screen dose study drug sufficiently minimize risk pregnancy point . Female subject must also agree use contraception throughout study two week last dose study medication . Body weight less equal 50 kg ( 110 lb . ) men less equal 45 kg ( 99 lb . ) woman body mass index ( BMI ) 18.5 28 kg/m2 inclusive . A signed date write informed consent obtain subject prior screening . The subject able understand comply protocol requirement , instruction protocolstated restriction likely complete study plan . As result medical interview , physical examination , screen investigation , Investigator considers subject unfit study . The subject 's systolic blood pressure outside range 90140 mmHg , diastolic blood pressure outside range 4590 mmHg heart rate outside range 45100 bpm male female subject . The subject 's body temperature &gt; 37.5 degree celcius . History/evidence symptomatic asymptomatic arrhythmia , angina/ischemia , coronary artery bypass graft surgery percutaneous transluminal coronary angioplasty congenital cardiac disease clinically significant cardiac disease . An episode cardiac syncope within one year screening period . History/evidence clinically significant pulmonary disease hyper/hypothyroidism . Has positive prestudy Hepatitis B surface antigen ; positive hepatitis C ( HCV ) antibody detectable HCV ribonucleic acid ( RNA ) ; positive HIV1 antibody result . Has history regular alcohol consumption average &gt; 7 drinks/week woman &gt; 14 drinks/week men ( 1 drink ( 12 g alcohol ) = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) 80 proof distil spirit ) within 6 month screen visit . Unwilling abstain alcohol 48 hour prior start dose collection final pharmacokinetic sample . Has history use tobacco nicotinecontaining product within 6 month screen visit . The subject positive prestudy drug and/or alcohol screen . Unwilling refrain use illicit drug adhere protocolstated restriction participate study . The subject receive investigational drug participate research trial within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose current study medication . Participation study would result donation blood excess 500 mL within 56 day period . History presence allergy intolerance study drug component drug class , history drug allergy , opinion physician responsible , contraindicate participation . In addition , heparin use PK sample , subject history sensitivity heparin heparin induce thrombocytopenia enrol . Use prescription nonprescription drug , include antacid , vitamin , herbal dietary supplement ( include St John 's Wort iron supplement ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator sponsor medication interfere study procedure compromise subject safety . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , total bilirubin , serum creatinine value great upper limit normal . A single repeat allow eligibility determination . Subjects preexist condition interfere normal gastrointestinal anatomy motility , hepatic and/or renal function , could interfere absorption , metabolism , and/or excretion study drug . Subjects history cholecystectomy pancreatitis exclude . History significant renal hepatic disease . History Gilbert 's syndrome . Has abnormal ECG describe protocol . Clinically significant anomaly electrolytes subject heart rate great equal 60/min</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>GSK1349572</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Japanese</keyword>
	<keyword>HIV</keyword>
</DOC>